Bicalutamide ('Casodex') development: from theory to therapy.
Kolvenbag
G J
GJ
Medical Affairs Department, Zeneca Pharmaceuticals, Wilmington, DE, USA.
Furr
B J
BJ
D000726:Androgen Antagonists / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D000813:Anilides / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D004195:Disease Models, Animal; D015195:Drug Design; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D008297:Male; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000188:drug therapy; D014105:Tosyl Compounds
D000726:Androgen Antagonists; D000813:Anilides; D000970:Antineoplastic Agents; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide